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Purpose or Objective: Although intensity modulated 
radiotherapy (IMRT) permits the delivery of a highly 
conformal dose to target volumes while sparing dose to 
identified organs at risk, it results in a higher whole body 
integral dose due to irradiation of a larger volume of tissue at 
lower doses. A randomized clinical trial in head and neck 
cancer comparing IMRT with 3-D conformal radiotherapy, 
demonstrated higher acute fatigue in the IMRT cohort, raising 
the possibility of an association with higher integral dose. We 
hypothesized that a higher integral whole body dose is 
associated with worsening fatigue and an adverse functional 
outcome in patients with localized prostate cancer treated 
with intensity modulated external beam radiotherapy.  
 
Material and Methods: 26 patients with localized 
adenocarcinoma of prostate treated with intensity modulated 
external beam radiotherapy were included in this analysis. 
The integral dose was calculated as the product of mean 
body dose and body volume and the study cohort was 
dichotomized using the median integral dose as the cut-off 
value. The fatigue, physical functioning and role functioning 
domains of the EORTC QLQ-C30 questionnaire prior to 
radiotherapy and upon completion of radiotherapy were 
assessed. The outcome measure was defined as worsening in 
any of these three domains. 
 
Results: The median integral dose was 119.7 litre-Gy (range 
90.5 – 168.1). In the whole population 17/26 (65%) had 
worsening of fatigue, physical or role functioning. A 
significantly higher proportion of patients with an integral 
dose above median had worsening fatigue, physical and role 
functioning compared with patients with an integral dose 
below median. (6/13 versus 11/13; z test for proportions 
p=0.04). 
 
Conclusion: To our knowledge, this is the first study linking 
acute worsening of fatigue and functional outcome with 
whole body integral dose. Further validation in a larger 
cohort and in different tumour sites is necessary and the 
relationship between integral dose and toxicity merits further 
investigation. 
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Purpose or Objective: To prospectively evaluate acute 
intestinal toxicity (AIT) from RT including whole-pelvis 
irradiation (WPRT) for prostate cancer by means of a 
validated questionnaire (IBDQ, Intestinal Bowel Disease 
Questionnaire), and to investigate the intestinal symptoms 
that most affect patient quality of life (QoL). 
 
Material and Methods: In 2014 a multicentric, observational 
trial aimed at assessing IT from RT including WPRT was 
activated. Prior to study activation, a pilot feasibility study 
was started in the coordinating Institute. For the study’s 
purpose, the IBDQ is to be filled in by pts at baseline, RT 
mid-point and end, 3 and 6 months, and thereafter every 6 
months up to 5 years. The questionnaire comprises 32 items 
investigating bowel symptoms (10 items), emotional health 
(12), systemic symptoms (5) and social function (5). The 
responses are scored on a seven-point scale in which 7 
corresponds to the best function and 1 to the worst. Average 
per item scores can be calculated for each of the 4 domains. 
This analysis pertains to the first 144 pts (8 Institutes) with 
complete data available at baseline, RT mid-point and end. 
Initially, only pts treated with post-prostatectomy RT with 
either adjuvant (ADV, n= 71) or salvage (SALV, n=73) intent 
were enrolled. Pts were treated with static-field IMRT 
(n=31), Tomotherapy (n=42) and VMAT (n=71), with 
conventional (1.8-2 Gy/fr, n=78) or moderate 
hypofractionation (2.15-2.65 Gy/fr, median 2.35, n=66). The 
median EQD2 dose to the prostatic bed and pelvic lymph-
nodal area was 71.2 and 50 Gy, respectively. 58 pts received 
concomitant androgen deprivation. 
 
Results: Overall, self-perceived intestinal toxicity from WPRT 
was mild: mean scores for bowel symptoms at baseline, RT 
mid-point and end were in fact 6.58, 6.09, 5.90 (repeated 
measures Anova, p<0.0001), for emotional health 
5.94,5.79,5.69 (0.0003), for social function 6.20, 5.83, 5.65 
(p<0.0001) and for systemic symptoms 5.95, 5.55, 5.40 
(p<0.0001), respectively. For the evaluation of acute toxicity, 
the worst variation (delta) between baseline and RT mid-
point or end was considered. With respect to the bowel 
symptoms, the median score decrease (worsening) was 2 
points for only one item (frequent bowel movements), 1 
point for loose bowel movements, gas passage, abdominal 
bloating and urge to defecate, and 0 for abdominal pains and 
cramps, rectal bleeding, accidental soiling and nausea. 
Nevertheless, abdominal pain and urge to defecate were the 
two items with higher predictive power (AUC 72-79% at ROC 
curve analysis) with respect to a worsening of ³1 point (25th 
percentile) of either emotional or systemic or social domains, 
as well as gas passage, urge to defecate and nausea (AUC 72-
73%) for emotional. 
 
Conclusion: The self assessed AIT from WPRT delivered by 
means of modern IMRT technique is negligible. Abdominal 
pain and urge to defecate are the 2 symptoms mostly 
correlated with a worsening of patient’s QoL. 
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Purpose or Objective: A new entity of patients with 
recurrent prostate cancer limited to a small number of active 
metastatic lesions is having growing interest: the 
oligometastatic patients. Patients with oligometastatic 
disease could eventually be managed by treating all the 
active lesions with local therapy, i.e. either surgery or 
ablative stereotactic body radiotherapy. This study aims to 
assess the impact of [18F]Choline ([18F]FMCH) PET/CT and 
the use stereotactic body radiotherapy (SBRT) in patients 
(pts) with oligometastatic prostate cancer (PCa). 
 
Material and Methods: Twenty-nine pts with oligometastatic 
PCa (≤3 synchronous active lesions detected with 
[18F]FMCHPET/CT) were treated with repeated salvage SBRT 
until disease progression (development of > three active 
synchronous metastases). Primary endpoint was systemic 
therapy-free survival measured from the baseline 
[18F]FMCHPET/CT. 
 
Results: A total of 45 lesions were treated with SBRT. After a 
median follow-up of 11.5 months (range 3-40 months), 20 pts 
were still in the study and did not receive any systemic 
therapy. Nine pts started systemic therapy, and the median 
time of the primary endpoint was 39.7 months (CI 12.20-
62.14 months). No grade 3 or 4 toxicity was recorded. 
 
Conclusion: Repeated salvage [18F]FMCHPET/CT-guided 
SBRT is well tolerated and could defer the beginning of 
systemic therapy in selected patients with oligometastatic 
PCa. 
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Purpose or Objective: 5-fraction SBRT using CyberKnife is a 
well-established safe alternative treatment for selected low-
risk (LR) and intermediate-risk (IR) prostate cancer.  
The aim of this study is to determine prospectively the 
morbidity (CTCAE) and QOL (auto-administered IPSS) of an 8-
fraction scheme for high-risk (HR), IR and LR using 
tomotherapy. 
 
Material and Methods: Exclusion criteria were T3b-4, GS 9-
10, PSA ≥50, IPSS ≥20.  
Since 2012 eighty-two patients were treated: 41 HR (23/41 
with GS ≥8 or PSA >20 or T3a, and 18/41 with ≥2 
intermediate risk factors), 17 IR (GS 7 or PSA 10-20 or T2b-c), 
and 24 LR.  
57/82 patients received 6-month hormonal therapy (HT).  
8 fractions of 5.65 Gy for HR-IR, and 5.48 Gy for LR patients 
were delivered every other day over about 2.5 weeks. EQD2 
is 92.3 Gy (HR, IR) or 87.4 Gy (LR) for prostate cancer (a/b 
1.5), and 78.2 or 74.3 Gy for late-responding tissues (a/b 3), 
respectively. 
 
Results: Median follow-up was 13.7 months (0.3-40.1). 
No acute/late grade ≥3 events were observed. Late GU or GI 
grade 2 toxicities were far bellow 10% (see Table). We 
observed a slight urinary flare at 18 months. 
 
  
During/following 
SBRT (N=81) 
1 
month 
(N=80) 
6 
months 
(N=66) 
12 
months 
(N=50) 
18 
months 
(N=35) 
24 
months 
(N=27) 
GU 
toxicity 
Grade 
1 41 50.6% 
17 
21.2% 
11 
16.7% 9 18% 3 8.6% 2 7.4% 
 
Grade 
2 17 21% 
3 
3.8% 0 0% 0 0% 2 5.7% 0 0% 
GI 
toxicity 
Grade 
1 26 32.1% 8 10% 6 9.1% 9 18% 7 20% 1 3.7% 
 
Grade 
2 10 12.4% 0 0% 1 1.5% 1 2% 1 2.9% 2 7.4% 
GU / GI 
toxicity 
Grade 
3+ 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 
 
IPSS scores (Q1-7) and patient satisfaction (Q8) returned to 
baseline at 6 months (p=0.21), after they significantly 
worsened at the last fraction (p=0.00), especially the IPSS-
obstructive component (see Figure). 
 
 
 
Without HT, PSA nadir has not been reached yet. Mean value 
at 24 months was 0.66 ng/mL.  
With HT, PSA nadir was reached between 1-6 months and 
then raised up to 0.37 ng/mL average at 18 months (mean 
testosterone 291 ng/dL), to remain steady afterwards. 
No biochemical (nadir+2) /clinical failure was found. One 
unrelated cancer/treatment death occurred during SBRT. 
 
Conclusion: To our knowledge this is the first communication 
of SBRT using helical tomotherapy for localized prostate 
cancer.  
The 8-fraction scheme is being well tolerated, with no 
moderate-severe toxicity, suggesting that this approach is 
safe.  
Longer follow-up is needed to find out whether the delivery 
of equivalent doses near the plateau of the dose-response 
curve (>90 Gy) results in better tumour control in this cohort 
of patients (mostly HR and IR tumours). 
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